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Abstract Recent interest focuses on urinary renin and
angiotensinogen as markers of renal renin-angiotensin sys-
tem activity. Before concluding that these components are
independent markers, we need to exclude that their presence
in urine, like that of albumin (a protein of comparable size),
is due to (disturbed) glomerular filtration. This review
critically discusses their filtration, reabsorption and local
release. Given the close correlation between urinary angio-
tensinogen and albumin in human studies, it concludes that,
in humans, urinary angiotensinogen is a filtration barrier
damage marker with the same predictive power as urinary
albumin. In contrast, in animals, tubular angiotensinogen
release may occur, although tubulus-specific knockout stud-
ies do not support a functional role for such angiotensino-
gen. Urinary renin levels, relative to albumin, are >200-fold
higher and unrelated to albumin. This may reflect release of
renin from the urinary tract, but could also be attributed to
activation of filtered, plasma-derived prorenin and/or in-
complete tubular reabsorption.
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Introduction
Renal angiotensin (Ang) II levels are several orders of
magnitude higher than circulating Ang II levels, and it is,
therefore, generally believed that renal Ang II originates at
renal tissue sites. Indeed, making use of infusions of 125I-
labeled Ang I and II, we were able to show that, despite
significant uptake of circulating 125I-labeled angiotensin II,
>90 % of renal Ang II could not be explained on the basis of
such uptake, and thus truly is derived from local synthesis
[1]. Where in the kidneys such generation occurs, and what
the effects of locally generated Ang II are, has been dis-
cussed elsewhere in detail [2–4]. An obvious question is
what determines such generation, i.e., where do the renin,
angiotensinogen and angiotensin-converting enzyme (ACE)
originate that together generate renal Ang II? A role for non-
ACE enzymes (e.g., chymase) seems unlikely given the
virtual absence of renal Ang II following ACE knockout [5].
Renin is made in the juxtaglomerular apparatus, and
released into the interstitial space, from where it may reach
the circulation via diffusion across the peritubular capillar-
ies. Proximal tubular fluid, however, also contains renin,
suggesting that circulating renin is filtered in the kidney
[6]. Unexpectedly, renin expression has also been observed
in the principal cells of the collecting duct [7]. Kang et al.
suggested that such expression is upregulated in the diabetic
kidney, and contributes to the elevated levels of prorenin
(the inactive precursor of renin) in patients with diabetic
nephropathy [8].
Circulating, liver-derived angiotensinogen diffuses into
the interstitium, reaching interstitial fluid levels that are
comparable to those in blood [9]. In addition, angiotensino-
gen mRNA has been demonstrated in the proximal straight
tubule, suggesting that angiotensinogen synthesis may also
occur locally in the kidney, independently of its synthesis in
the liver [4].
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Circulating ACE plays little, if any, role, and, thus, renal
Ang II generation will depend entirely on locally expressed,
membrane-bound ACE in the kidney [10]. Indeed, in the
human kidney, ACE is abundant in the brush border of the
proximal tubule, and, remarkably, usually absent in endo-
thelial cells of any vessel type [11]. Endothelial neoexpres-
sion of ACE comes into play in different diseases, e.g.,
diabetes mellitus and chronic arterial hypertension [11].
Recent interest focuses on the occurrence of both renin and
angiotensinogen in urine, as markers of renal renin-angiotensin
system (RAS) activity, potentially reflecting the disease state
[12•, 13]. If indeed the renal levels of both proteins reflect their
production at renal tissue sites, their measurement would be a
simple manner to determine whether the renal RAS is upregu-
lated, thus reinforcing the need for treatment with a RAS
blocker. However, before drawing this conclusion, we need to
be certain that these urinary proteins, like albumin, do not
simply reflect breakdown of the glomerular filtration barrier,
i.e., that they are kidney- and not plasma-derived. If plasma-
derived, their clinical value on top of a much cheaper urinary
albumin measurement needs to be proven.
This review summarizes all current findings on urinary
angiotensinogen and renin. It will also discuss the presence
of prorenin in urine. Given the less abundant literature on
urinary ACE, it does not focus on this RAS component.
Moreover, it will also not address urinary aldosterone and
Ang II, since these peptides are much smaller and thus
highly likely to easily filter from the circulation. Indeed,
all urinary aldosterone is plasma-derived [12•], and thus
urinary aldosterone is a well-established parameter of
changes in circulating aldosterone.
Urinary Angiotensinogen
Animal Studies. Infusing Ang II (40 ng/min) in rats on top of
a high-salt diet (8 %) not only raised the renal Ang II
content, but also increased the urinary angiotensinogen ex-
cretion 4-fold, from 1 to 4 nmol/day [14]. At a rat urinary
volume of ≈10 mL/day, this corresponds with urinary angio-
tensinogen levels of 100–400 pmol/mL. Given earlier
reports on angiotensinogen expression in proximal tubular
cells [15], and the fact that in this study urinary angiotensi-
nogen excretion correlated with renal Ang II but not plasma
Ang II, it was suggested that urinary angiotensinogen
reflects renal Ang II production. Surprisingly, Ang II in fact
stimulated renal angiotensinogen synthesis, resulting in both
elevated renal angiotensinogen levels and increased urinary
angiotensinogen excretion, thus, potentially creating a pos-
itive feed-forward loop [16]. According to this concept, the
rise in renal Ang II content following Ang II infusion
involves de novo Ang II formation in the kidney from
locally generated angiotensinogen [17].
When interpreting these results, it should be kept in mind
that Ang II also raised blood pressure and is known to
stimulate hepatic angiotensinogen production [18]. In com-
bination with the deleterious effects of Ang II on glomerular
barrier function, occurring, at least in part, due to the rise in
blood pressure, an alternative explanation of these findings
is therefore that they reflect increased filtration of circulat-
ing, liver-derived angiotensinogen, particularly when its
levels are increased [19•]. Moreover, infusing 125I-labeled
Ang II results, via Ang II type 1 (AT1) receptor-mediated
endocytosis [20, 21], in renal 125I-Ang II levels that, per
gram wet weight, are ≈4-5-fold higher than the plasma 125I-
Ang II levels per mL at steady state [22]. Thus, the rise in
renal Ang II following Ang II infusion in rats could be easily
attributed to AT1 receptor-mediated endocytosis of infused
Ang II.
Interestingly, under high-salt conditions, male rats dis-
played a higher rise in urinary angiotensinogen excretion
than female rats during Ang II infusion [23]. Although this
could be attributed to the higher renal angiotensinogen
mRNA expression in males exposed to Ang II and high salt,
an alternative explanation is the higher degree of proteinuria
in the male rats of this study, which would be accompanied
by increased filtration of circulating angiotensinogen. The
urinary angiotensinogen levels in this study ranged from
≤0.1 (control) to >30 ng/day (after Ang II infusion) per
gram body weight. At a body weight of ≈250 g and a urinary
volume of ≈10 mL/day, this would correspond with urinary
angiotensinogen concentrations of 2.5–750 ng/mL (0.04–
12 pmol/mL). Thus, the control angiotensinogen levels in
this study are >1000-fold lower than those in the above
described studies.
Rats exposed to deoxycorticosterone acetate plus high
salt display hypertension but not elevated Ang II levels. In
this model, urinary angiotensinogen remained in the normal
range (1 nmol/day) [24]. Yet, the Dahl salt-sensitive rat,
when put on a high-salt diet (suppressing the circulating
RAS) did display inappropriately elevated renal and urinary
angiotensinogen levels in the face of hypertension [25].
Other models evaluating renal dysfunction in the presence
of low-to-normal circulating RAS activity (e.g., mice with
diabetic nephropathy [26] or IgA nephritis [27] and sponta-
neously hypertensive rats [28]) also displayed elevated uri-
nary angiotensinogen levels. This could be suggestive for an
activated renal RAS, as is believed to exist in diabetes
mellitus [29]. If, however, this involves increased renal
angiotensinogen expression and the subsequent release of
this angiotensinogen into urine, the question is whether the
increased renal angiotensinogen expression is the cause or
consequence (feed-forward concept) of the elevated renal
Ang II levels. The urinary angiotensinogen excretion in
diabetic mice amounted to 250 μg/day (vs. 20 μg/day in
controls) at three days after the induction of diabetes.
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Interestingly, in that same time period, while on insulin
treatment, the urinary volume also increased ≈10-fold (from
1–1.5 to 10–15 mL/day), implying that the actual urinary
angiotensinogen concentration did not change. The urinary
angiotensinogen concentration in IgA nephritic mice was
15 ng/mL, threefold higher than in control mice. Assuming
a mouse urinary volume of ≈1 mL/day, this would imply
that these mice excreted 15 ng angiotensinogen/day (vs.
5 ng/day in controls), i.e., >1000-fold less than the mice of
the diabetes study.
Taken together, the current animal studies report a wide
range (>1000-fold) of urinary angiotensinogen concentra-
tions, even in normal controls, and these levels are, confus-
ingly, presented either per animal per day, per g body weight
per day or per mL, and in either grams or moles. Only rarely,
plasma and urinary angiotensinogen levels have simulta-
neously been determined [27]. Unfortunately, the plasma
levels were often reported in densitometric units on the basis
of Western blot analysis [25], thus not allowing a compar-
ison with the actual urinary levels of angiotensinogen. This
raises the need for a reference protein in urine, preferably of
identical size. An obvious candidate is albumin, which has a
comparable molecular weight (67 kD vs. 65 kD), and is a
well-established marker of nephropathy. Since urinary albu-
min is generally believed to be entirely plasma-derived, a
careful comparison of the urinary albumin and angiotensi-
nogen levels would clarify to what degree urinary angioten-
sinogen is plasma-derived as well.
Human Studies. Unfortunately, data on the urinary albumin
levels in the above animal studies are scarce. Yet, ample
studies have evaluated the two proteins in urine in humans.
In fact, in these studies, without exception, a strong corre-
lation was observed between urinary angiotensinogen and
albumin [12•, 13, 30, 31]. To study angiotensinogen inde-
pendently of this relation, Saito et al. selected 28 type 1
diabetes mellitus patients without microalbuminuria, and
still observed a 3-fold rise (from 4 to 12 μg angiotensino-
gen/g creatinine) in urinary angiotensinogen versus 21 con-
trols, although this rise was borderline for significance
(P=0.045). In type 2 diabetes mellitus patients, urinary
angiotensinogen (10–150 μg angiotensinogen/g creatinine)
correlated strongly with the albumin/creatinine ratio, and
predicted the annual decline in the estimated glomerular
filtration rate (eGFR) over a 10-year period. Not surprising-
ly, the patients with both albuminuria and high urinary
angiotensinogen levels showed the worst decline of eGFR,
and a higher incidence of renal and cardiovascular compos-
ite endpoints [30]. Unfortunately, no rigorous statistical
analysis was performed to determine the independency of
the effect of angiotensinogen and albumin on eGFR decline.
Such an analysis was performed in 201 patients with chronic
kidney disease (eGFR <60 mL/min/1.73 m2 or presence of
albuminuria at ≥30 mg/24 hr) [31]. Their urinary angioten-
sinogen levels were 6-fold elevated vs. 201 controls
(26.3 vs. 4.4 μg/g creatinine), and correlated highly signif-
icantly with urinary albumin. Moreover, both urinary angio-
tensinogen and urinary albumin correlated negatively
with eGFR. However, when correcting for albumin, the
angiotensinogen-eGFR association remained significant.
Thus, elevated urinary angiotensinogen levels on top of
elevated urinary albumin levels independently determined
eGFR decline. Yet, the analysis did not correct for the
elevated plasma angiotensinogen levels that were observed
in the patients with chronic kidney disease of this study, and
thus it cannot be excluded that the independent effect of
urinary angiotensinogen in reality, via glomerular filtration,
reflects the activation of the systemic RAS. Yamamoto et al.
[32] confirmed the association between urinary angiotensi-
nogen and eGFR decline in patients with chronic kidney
disease, and additionally showed that the AT1 receptor an-
tagonist losartan reduced urinary angiotensinogen. Impor-
tantly, losartan also reduced plasma angiotensinogen, albeit
to a lesser degree. Unfortunately, no comparison with uri-
nary albumin was made in this study.
In hypertensive patients with a preserved kidney func-
tion, the urinary angiotensinogen/creatinine ratio correlated
with blood pressure and the urinary albumin/creatine ratio
[13]. Treatment with RAS blockers decreased the urinary
angiotensinogen/creatinine ratio in these patients to levels
that were also observed in normotensive controls (from 25
to 14 μg/g creatinine). This decrease was comparable to that
in urinary albumin (from 132 to 29 mg/g creatinine). A
correlation between blood pressure and the urinary angio-
tensinogen/creatinine ratio was even observed after exclud-
ing patients with diabetes mellitus or patients who were
receiving antihypertensive treatment, in the Bogalusa Heart
Study [33]. Lantelme et al. [34] observed a relationship
between urinary angiotensinogen and blood pressure only
in women with essential hypertension and a low plasma
renin/aldosterone ratio, and not in men with this type of
hypertension, nor in patients with other types of essential
hypertension.
Elevated urinary angiotensinogen/creatinine ratios have
been observed in IgA nephropathy in several studies [35,
36], and kidney biopsies of such patients confirmed upregu-
lated expression of angiotensinogen and enhanced Ang II
immunoreactivity [36]. Treatment of patients with IgA ne-
phropathy with an AT1 receptor antagonist (valsartan) re-
duced urinary angiotensinogen [36]. Furthermore, the
sodium sensitivity index (i.e., the reciprocal of the slope of
the pressure-natriuresis curve drawn by linking the data-
points obtained during a normal- and a low-salt diet) in IgA
nephropathy patients correlated positively with the log-
transformed urinary angiotensinogen/creatinine ratio (17.5 vs.
7.9 μg/g, normal vs. low-salt), but not with the urinary protein
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excretion [37]. However, when analyzing the data, protein
excretion was neither corrected for creatinine, nor analyzed
with a non-parametric approach despite its usual non-normal
distribution, thus making a true comparison with angiotensi-
nogen difficult.
Summarizing, the variation in urinary angiotensinogen
levels in humans is much smaller than in rodents, and the
levels in healthy individuals are in a very close range:
usually <10 μg/g creatinine, or, at a creatinine level of
≈1 g/L, 10 ng angiotensinogen/mL, i.e., 0.2 pmol/mL. This
is several orders of magnitude lower than the urinary levels
reported in rodents. Human values were in most cases log-
transformed prior to analysis. Studies that also determined
urinary albumin or protein usually found a close correlation
between these parameters and urinary angiotensinogen, in-
cluding the changes that occurred following RAS blockade.
In the rare cases that the associations between urinary angio-
tensinogen and disease parameters were independent of or
different from albumin (or protein), either the albumin (or
protein) data were differently expressed (i.e., not corrected
for creatinine and non-log-transformed [37]) or the changes
in circulating angiotensinogen were not taken into consider-
ation [31]. The latter is of the utmost importance, to rule out
that urinary angiotensinogen truly behaves independently of
circulating angiotensinogen. Indeed, when correcting uri-
nary angiotensinogen for plasma angiotensinogen in 101
hypertensive patients with or without diabetes mellitus, we
observed that urinary angiotensinogen in all aspects mim-
icked urinary albumin [12•].
Filtration Versus Local Synthesis. An elegant study in mice
by Nakano et al. has recently investigated to what degree
infused human angiotensinogen filters into urine, simulta-
neously making a comparison with albumin [38••]. Both
proteins were fluorescently labeled and applied via bolus
injection into the carotid artery. Immediately thereafter,
fluorescence was measured in Bowman’s space and the
glomerular capillaries to determine glomerular permeability.
The data revealed that almost no labeled human angiotensi-
nogen showed up in Bowman’s space (four times less than
labeled albumin), and that its urinary levels were below the
detection limit. Increased sieving of angiotensinogen did
occur with an increasing level of glomerulosclerosis, but
not to a degree that would explain the rise in urinary angio-
tensinogen in this condition. Here it should be acknowl-
edged that both Richoux et al. and Pohl et al. [19•, 39]
have demonstrated that angiotensinogen does occur in the
ultrafiltrate, but is largely removed via endocytotic uptake in
the tubulus, in a megalin-dependent manner. Endocy-
tosed angiotensinogen is subsequently degraded, and
the amount of angiotensinogen in the proximal convo-
luted tubules correlated closely with the plasma level of
angiotensinogen [39].
Importantly, in the Nakano et al. study [38••], the glo-
merular permeability of infused human angiotensinogen
correlated with the urinary albumin levels, but not with the
urinary rodent angiotensinogen levels. The authors therefore
proposed that endogenous urinary angiotensinogen originat-
ed in the kidney, most likely in the tubules. They detected
urinary mouse angiotensinogen levels of ≈2 ng/90 minutes
versus ≈2000 ng/mL in plasma. In rats developing glomer-
ulosclerosis, the urinary angiotensinogen levels were
≈30 ng/90 minutes at young age, and these levels increased
to ≈100 ng/90 minutes at older age. Given the urinary
volume of rodents of at most a few mL per day, this implies
that in these animals the endogenous angiotensinogen levels
in urine, like in all previous rodent studies, were several
orders of magnitude above those in humans.
When considering the absence of human angiotensinogen
in rodent urine in the above study, it should be taken into
account that the application of a bolus injection will not result
in a stable steady-state level of angiotensinogen in blood.
Nakano et al. measured circulating angiotensinogen at one
time point (90 minutes after injection), and found it to be equal
to the level of endogenous mouse angiotensinogen. However,
angiotensinogen, like renin, normally diffuses into the inter-
stitium [9, 40], reaching interstitial levels that are comparable
to those in plasma [41–43]. Consequently, a substantial
amount of the infused human angiotensinogen would be
expected to diffuse into the interstitial space in the first few
hours post-injection, thereby potentially limiting its accumu-
lation in urine. Normal angiotensinogen levels in human urine
are ≈0.2 pmol/mL (see above), versus ≈1200 pmol/mL in
plasma, i.e., the urinary levels are at most 0.01 % of the
plasma levels. It is, therefore, likely that, in mice, the urinary
levels of human angiotensinogen, in view of its whole-body
distribution, remained <0.01 % of its post-injection plasma
level, i.e., (far) below the detection limit of the applied assay.
A similar line of reasoning applies to a study where the
authors failed to detect human angiotensinogen in rat urine
following its intravenous injection [24].
A unifying concept, given the >100-fold higher urinary
angiotensinogen levels in rodents, might be that in humans
urinary angiotensinogen is exclusively plasma-derived,
hence, its close correlation with albumin, whereas in rodents
it is indeed largely kidney (proximal tubule)-derived (see
Fig. 1). To investigate the physiological importance of such
kidney-derived angiotensinogen, a kidney-specific angio-
tensinogen knockout mouse has been developed [44••].
Unexpectedly, such mice had renal angiotensinogen and
Ang II levels that were identical to those in control mice,
both under normal conditions and following podocyte inju-
ry. Thus, it was concluded that, even if angiotensinogen is
synthesized in the kidney, it has no functional role, i.e., it
does not contribute to renal angiotensin production. This
contradicts the feed-forward loop between Ang II and renal
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angiotensinogen [16], but would still imply that (non-func-
tional) angiotensinogen in the urine of rodents provides an
indication of the amount of Ang II to which the kidney
(proximal tubule) is exposed. Clearly, evidence is now
needed to what degree this holds true in animal models with
severe glomerular damage, resulting in increased filtration
of plasma proteins, including albumin and angiotensinogen.
Urinary Renin and Prorenin
Renin was originally described in human urine by Lumbers
and Skinner [45, 46]. They found no relationship with urinary
creatinine or urinary protein, nor with plasma renin. On aver-
age, the urinary renin level was ≈7 % of that in plasma.
Remarkably, although women normally have lower plasma
renin levels than men [47], their urinary renin levels were
higher. Natriuretic therapy (spironolactone + chlorothiazide)
elevated plasma renin 5-fold, but only modestly increased
urinary renin. As a consequence, renin clearance (mL plas-
ma/24 hours) fell by >50 %, whereas protein clearance fell by
≈20 %. The authors concluded that during sodium depletion
either increased tubular reabsorption of renin had occurred, or
that urinary renin originated from the urinary tract (tubular
sites and/or the collecting duct). In case of the latter, such local
renin release then apparently remained relatively constant in
the face of increased circulating renin levels.
Yukimura et al. confirmed the modest role of urinary
excretion in the metabolism of renin, and were unable to
demonstrate prorenin in the urine of dogs [48]. Unlike
Lumbers and Skinner, these authors did see a rise in urinary
renin excretion when elevating plasma renin in dogs, al-
though in this case plasma renin was elevated by injecting
semipurified kidney renin. Mazanti et al. found that renin in
mouse urine was two orders of magnitude lower than in
plasma, and also observed an increase in urinary renin
following injection of exogenous renin [49]. Importantly,
when blocking tubular reabsorption with lysine, urinary
renin rose >100-fold, without altering plasma renin [49].
This suggests that normally, ultrafiltered renin is reabsorbed
almost completely. Indeed, Pohl et al. confirmed such reab-
sorption, and suggested that it involves megalin, since im-
munoreactive renin could not be demonstrated in the
proximal tubulus of mice lacking tubular megalin [19•].
Nielsen et al. observed very little, if any, prorenin in mouse
urine [50]. However, after lysine, prorenin levels in urine
became detectable, and the authors were able to estimate
that the urinary clearance of prorenin in the absence of
tubular reabsorption was ≈10-fold lower than that of renin.
In a recent study involving 101 diabetic and non-diabetic
patients with or without hypertension, we observed urinary
renin levels that were around ≈6 % of those in plasma [12•],
identical to the observations by Lumbers and Skinner [45,
46]. Prorenin was undetectable in urine in our hands, and
Fig. 1 Overview of the origin of urinary renin and angiotensinogen. In
humans, angiotensinogen in urine correlates closely with albumin, and
thus, like albumin, reaches urine via glomerular filtration from plasma.
Levels range from <10–150 μg/g creatinine, or (assuming a creatinine
content of ≈1 g/L), <10–150 ng/mL (i.e., <0.2–2 pmol/mL). This
corresponds with <0.01–0.1 % of the plasma angiotensinogen levels
in humans. In rodents, urinary angiotensinogen levels are usually
much higher, and range from <0.5–4000 pmol/day, or (assuming a
urinary volume of ≈1 mL/day in mice and ≈10 mL/day in rats)
<0.1–400 pmol/mL. This implies that the urinary angiotensinogen
levels in rodents sometimes are higher than their plasma levels.
Such high levels could reflect angiotensinogen release from renal
tissue sites, possibly the proximal tubule. Urinary renin levels in
humans were 5–10 % of the plasma renin levels, i.e., 1–2 orders of
magnitude higher than the corresponding urinary levels of albumin
and angiotensinogen. Prorenin was undetectable in urine. Most
likely, therefore, urinary renin has 3 sources: filtration from plasma,
release from the urinary tract (possibly the collecting duct), and
intrarenal conversion of (plasma-derived) prorenin to renin
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this was not due to prorenin-renin conversion in urine, since
adding prorenin to urine did not result in renin generation.
Renin in urine was unrelated to urinary albumin or angioten-
sinogen, and relative to these proteins >200-fold higher. Uri-
nary renin did not correlate with plasma renin or prorenin.
Unexpectedly, urinary renin decreased in patients treated with
a RAS blocker (despite their elevated plasma renin levels),
and increased in diabetics (despite their lower plasma renin
levels). This would be in agreement with the concept that
urinary renin is derived from the distal nephron, i.e., the
collecting duct, and that Ang II stimulates the release of
renin/prorenin from this site, as opposed to its inhibitory role
towards renin release from the juxtaglomerular cells. Indeed,
several animal studies support the concept of renin synthesis
in the principal cells of the collecting duct, and its upregula-
tion by Ang II and diabetes mellitus [7, 8, 51].
The inability to detect prorenin in human urine may be so
for several reasons. First, concentrations may be too low to
detect, implying that prorenin is not filtered to the same degree
as renin, reabsorbed to a greater degree, and/or not released
from the collecting duct. Second, proteolytic cleavage of
filtered prorenin may have occurred in the kidney, during the
formation of urine. Clearly, such cleavage does not occur in
urine per se (given our inability to observe prorenin-renin
conversion when adding prorenin to urine ex vivo), although
at the same time it is known that the kidneys are the only sites
in the body where prorenin-renin conversion occurs [52, 53].
In summary, it appears that circulating renin is filtered in
the glomerulus (given its presence in proximal tubular fluid
[54]), but subsequently highly efficiently reabsorbed in the
proximal tubule (see Fig. 1). This resembles the renal han-
dling of circulating angiotensinogen [19•]. For unknown
reasons, filtration of circulating prorenin tends to occur to
a lesser degree, and is likely to be followed by proteolytic
cleavage to renin in the urinary system, thus explaining why
urinary prorenin is undetectable in most studies. In addition,
there may be Ang II-stimulated renin release from the col-
lecting duct. This would explain why urinary renin levels
are far above those of albumin and angiotensinogen, and do
not run in parallel with changes in plasma renin.
Conclusion
In humans, urinary angiotensinogen correlates closely with
urinary albumin, and when carefully correcting for changes in
circulating angiotensinogen, there is as yet no convincing
evidence that there are conditions where urinary angiotensi-
nogen behaves independently of urinary albumin. Therefore,
urinary angiotensinogen, like albumin, clearly is a marker of
renal disease, and the measurement of both proteins offers the
same information. Interestingly, using a proteomics approach,
Alge et al. recently identified urinary angiotensinogen and
albumin as the two strongest biomarkers in patients with acute
kidney injury predicting the need for renal replacement ther-
apy [55]. These investigators subsequently confirmed the
prognostic predictive power of urinary angiotensinogen in
97 patients who underwent cardiac surgery for the develop-
ment of acute kidney injury. Unfortunately, they did not verify
the prognostic power of urinary albumin, despite the many
studies that support such a role [56–58].
In rodents, there may be a release of non-functional angio-
tensinogen into urine from proximal tubular synthesis sites.
Ang II stimulates such release. Remarkably, this angiotensi-
nogen neither contributes to the renal angiotensinogen content
nor to the renal Ang II levels [44••], implying that all func-
tionally renal angiotensinogen is liver-derived. Liver-derived
angiotensinogen may reach renal tissue sites via diffusion into
the interstitium and/or glomerular filtration.
Urinary renin potentially has three sources: filtration
from plasma, release from the collecting duct, and intrarenal
conversion of (plasma-derived) prorenin to renin. Normally,
filtered renin is highly efficiently reabsorbed, and the same
applies to filtered prorenin. Thus, most urinary renin would
then be derived from the collecting duct. Only when greatly
elevating circulating renin (e.g., by infusing exogenous re-
nin or by blocking the RAS highly efficiently), tubular
reabsorption falls short, allowing plasma renin to also accu-
mulate in urine. The same will occur when plasma prorenin
levels are elevated, provided that filtered prorenin is con-
verted to renin in the urinary system. Thus, an alternative
explanation for the elevated urinary renin levels in diabetics
vs. non-diabetics is that it is the consequence of their ele-
vated prorenin levels [12•, 47]. Clearly, we need prospective
studies evaluating the use of urinary renin as an independent
marker, e.g., to establish the renal efficacy of RAS blockers
and renal RAS activity in diseases such as diabetes mellitus
and CKD.
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